Category Jumplist
Jumplist
- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Emergent To Make Drug Substance For J&J's COVID-19 Vaccine Candidate
Johnson & Johnson had struck a deal with Emergent in April to use its manufacturing facilities and make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.
Photo Credit :
1594033643_zF0FeK_2020_07_06T105256Z_1_LYNXMPEG650O7_RTROPTP_4_HEALTH_CORONAVIRUS_INDIA_BHARAT_BIOTECH.JPG
![]()
Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.
Johnson & Johnson had struck a deal with Emergent in April to use its manufacturing facilities and make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.
(Reuters)